Pavmed Inc (PAVM)
$0.60 +0.00 (0.25%)Market Cap | 11.34M |
Revenue (ttm) | 3.00M |
Net Income (ttm) | 39.79M |
EPS (ttm) | N/A |
PE Ratio | 0.00 |
Forward PE | N/A |
Profit Margin | 1,326.33% |
Debt to Equity Ratio | 0.00 |
Volume | 447,400 |
Avg Vol | 176,974 |
Day's Range | N/A - N/A |
Shares Out | 16.79M |
Stochastic %K | 4% |
Beta | 1.13 |
Analysts | Sell |
Price Target | $9.00 |
Latest News on PAVM

Apr 3, 2025, 9:00 AM EDT - 6 days ago
Lucid Diagnostics to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference

Mar 27, 2025, 8:01 AM EDT - 13 days ago
Lucid Diagnostics Launches "Embrace the Future" Campaign Showcasing EsoCheck's Groundbreaking Collect+Protect Esophageal Cell Collection Technology

Mar 25, 2025, 8:01 AM EDT - 15 days ago
PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 24, 2025, 8:01 AM EDT - 16 days ago
Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 20, 2025, 8:31 AM EDT - 20 days ago
Lucid Diagnostics Announces Updated National Comprehensive Cancer Network® (NCCN) Guidelines Now Include Esophageal Precancer Screening

Mar 18, 2025, 8:31 AM EDT - 22 days ago
Lucid Diagnostics' ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication

Mar 13, 2025, 7:36 AM EDT - 27 days ago
Lucid Diagnostics Secures First Positive Commercial Insurance Coverage Policy for its EsoGuard® Esophageal DNA Test

Mar 10, 2025, 9:01 AM EDT - 4 weeks ago
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 24, 2025

Mar 5, 2025, 4:45 PM EST - 4 weeks ago
Lucid Diagnostics Announces Closing of $15.3 Million Registered Direct Offering

Mar 4, 2025, 8:25 AM EST - 5 weeks ago
Lucid Diagnostics Announces $15.3 Million Registered Direct Offering

Feb 27, 2025, 8:31 AM EST - 5 weeks ago
Renowned Investigators Awarded $8 Million NIH Grant to Study Lucid Diagnostics' EsoGuard® in At-Risk Patients without Symptomatic GERD

Feb 25, 2025, 8:31 AM EST - 6 weeks ago
Lucid Diagnostics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Feb 24, 2025, 8:31 AM EST - 6 weeks ago
PAVmed and Subsidiary Veris Health Complete Private Placement Financing

Feb 20, 2025, 8:31 AM EST - 6 weeks ago
Lucid Diagnostics Executes First Concierge Medicine Contract with LEAA Health

Feb 18, 2025, 8:30 AM EST - 7 weeks ago
PAVmed Regains Compliance with Nasdaq Stockholders' Equity Requirement

Feb 6, 2025, 8:57 AM EST - 2 months ago
Lucid Diagnostics to Participate in the 12th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Jan 13, 2025, 7:56 AM EST - 3 months ago
Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume

Dec 23, 2024, 8:01 AM EST - 3 months ago
Lucid Diagnostics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

Dec 19, 2024, 8:01 AM EST - 3 months ago
Lucid Diagnostics Partners with VITALExam to Enhance Esophageal Precancer Detection for Firefighters

Dec 11, 2024, 8:01 AM EST - 4 months ago
Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed Publication

Dec 3, 2024, 8:01 AM EST - 4 months ago
Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term Milestones

Nov 20, 2024, 7:56 AM EST - 5 months ago
Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test

Nov 18, 2024, 8:15 AM EST - 5 months ago
Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

Nov 14, 2024, 8:01 AM EST - 5 months ago
PAVmed Provides Business Update and Third Quarter 2024 Financial Results

Nov 13, 2024, 8:01 AM EST - 5 months ago
Lucid Diagnostics Provides Business Update and Third Quarter 2024 Financial Results


Nov 5, 2024, 8:01 AM EST - 5 months ago
Lucid Diagnostics Expands Direct Contracting Initiative with Multiple Programs Focused on Near-Term Revenue Drivers

Oct 31, 2024, 8:31 AM EDT - 5 months ago
PAVmed to Hold a Business Update Conference Call and Webcast on November 14, 2024

Oct 30, 2024, 8:31 AM EDT - 5 months ago
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 13, 2024

Oct 15, 2024, 7:51 AM EDT - 6 months ago
Lucid Diagnostics Receives Notice of Allowance for Key Patent Underlying Its EsoGuard Esophageal DNA Test

Oct 10, 2024, 7:51 AM EDT - 6 months ago
PAVmed Subsidiary, Veris Health, Awarded $1.8 Million NIH Grant to Enhance Cancer Care

Oct 9, 2024, 8:01 AM EDT - 6 months ago
Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Virtual Summit

Oct 8, 2024, 7:49 AM EDT - 6 months ago
Lucid Diagnostics to Join Global Medtech Leaders at The MedTech Conference 2024

Sep 24, 2024, 8:01 AM EDT - 7 months ago
American Foregut Society's 2024 Annual Meeting to Highlight Lucid Diagnostics' EsoGuard Esophageal Precancer Test

Sep 16, 2024, 4:30 PM EDT - 7 months ago
PAVmed Announces Efforts to Regain Compliance with Nasdaq Listing Requirements


Sep 3, 2024, 7:51 AM EDT - 7 months ago
Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile Health

Aug 20, 2024, 8:16 AM EDT - 8 months ago
Lucid Diagnostics Announces Publication of Analytical Validation Study of EsoGuard® for Early Detection of Esophageal Precancer and Cancer

Aug 13, 2024, 8:16 AM EDT - 8 months ago
The American Foregut Society Formally Requests Medical Policy Coverage of EsoGuard® to Enhance Early Detection of Esophageal Cancer

Aug 13, 2024, 8:01 AM EDT - 8 months ago
PAVmed Provides Business Update and Second Quarter 2024 Financial Results

Aug 12, 2024, 8:07 AM EDT - 8 months ago
Lucid Diagnostics Provides Business Update and Second Quarter 2024 Financial Results

Aug 8, 2024, 8:31 AM EDT - 8 months ago
Lucid Diagnostics Holds First Major Directly-Contracted EsoGuard® #CheckYourFoodTube Precancer Testing Event

Aug 6, 2024, 8:15 AM EDT - 8 months ago
Lucid Diagnostics Announces Positive Data from ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing

Aug 5, 2024, 8:15 AM EDT - 8 months ago
Lucid Diagnostics to Participate in Upcoming Investor Conferences

Jul 30, 2024, 8:15 AM EDT - 9 months ago
PAVmed to Hold a Business Update Conference Call and Webcast on August 13, 2024

Jul 29, 2024, 8:15 AM EDT - 9 months ago